You searched for "nAMD"
Research is everyone’s business @ 100% Ophthalmology
@16:15 – 17:00 The NHS Constitution pledges to inform patients of research studies in which they may be eligible to participate. The NHS Long Term Plan states that research will play a key part in improving the quality of patient care and health outcomes. The various professional regulatory bodies have mandated that registrants demonstrate an understanding of research, ethics and governance in order to apply research findings and inform best practice. Therefore, all staff working in health and social care are required to have an awareness of research as pertains to their practice. This session will explore how staff can incorporate research into their practice to make it business as usual.What’s new in wet AMD papers?
Paper presentations on neovascular (‘wet’) age-related macular degeneration (AMD) from the 16th European Society of Retina Specialists Congress, Copenhagen, September 2016, outline recent research directions evaluating the impact of vision loss on key health domains, patient preferences in the process...Patients blinded by stem cells! How safe are they really?
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: Patients blinded by stem cells! How safe are they really? Ever since the successful results following...inserts
Eye News April/May 2022Independent Opticians Win SightCare Excellence Awards at the 2022 SightCare Business & Networking Conference
Six deserving independent optical practices were named as winners in the 2022 SightCare Awards celebrating the independent spirit.Real world data of post-IVT endophthalmitis, from a nurse-delivered intravitreal injection service
Introduction Intravitreal injection of neutralising anti-vascular endothelial growth factor (VEGF) antibody was licenced more than a decade ago, and over the years there has been proportionate increase in the number of intravitreal injections [1]. Injection of a therapeutic agent through...
Age-related macular degeneration
This review article offers an up to date review of the genetic and environmental risk factors associated with aetiology surrounding age-related macular degeneration (AMD). The article briefly describes the typical clinical presentation relating to early and late stages of the...Celebrating eight years of the nurse-led intravitreal injection service
Moorfields Eye Hospital NHS Foundation Trust in London celebrated the eighth year of its nurse-led intravitreal (IVT) injection service in 2020. In collaboration with Beaver-Visitec International (BVI), Moorfields’ comprehensive one-day course for non-medical staff has blossomed into a thriving success....
Four year outcomes of macular degeneration treated with ranibizumab
The authors report on a retrospective study of neovascular age-related macular degeneration (AMD) patients treated with a variable ranibizumab dosing regimen over a period of four years (from January 2007 to December 2011). A total of 600 treatment naïve eyes...Pegcetacoplan: A breakthrough treatment for dry age-related macular degeneration?
Age-related macular degeneration (AMD) is a degenerative condition affecting the macula, the part of the retina responsible for central vision. It is characterised by the presence of drusen and retinal pigment epithelium (RPE) abnormalities in the absence of other macular...
Features of AMD treatment non-responders
This is a retrospective consecutive case series of 365 eyes with age-related macular degeneration (AMD) who had three monthly intravitreal aflibercept treatments for at least 12 months. Responders were defined as complete resolution of exudation, intraretinal oedema, subretinal fluid, pigment...
